Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Phio Pharmaceuticals Corp. (PHIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.7300+0.0073 (+1.01%)
At close: 04:00PM EDT
0.7400 +0.01 (+1.37%)
After hours: 07:38PM EDT
Advertisement

Phio Pharmaceuticals Corp.

257 Simarano Drive
Suite 101
Marlborough, MA 01752
United States
508 767 3861
https://www.phiopharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees12

Key Executives

NameTitlePayExercisedYear Born
Dr. Gerrit Dispersyn Dr. Med. Sc, Ph.D.Pres, CEO & Director583.14kN/A1975
Ms. Caitlin KontulisVP of Fin. & Admin. and Sec.N/AN/A1986
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Corporate Governance

Phio Pharmaceuticals Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement